Marion Merrell Dow, Inc.

SPE ANTEC 2022. Photo Credit: SPE ANTEC SPE ANTEC 2023, taking place March 27-30, 2023 at the Hilton Denver City Center in Denver, Colorado, features a technical program that includes 18 tracks with more than 115 sessions as well as three keynote presentations, all focused on the latest advances in industrial, national laboratory and academic work in plastics and composites. For professionals looking to build their plastics and composites knowledge and take that information back to their projects and processes, SPE’s ANTEC 2023 technical program will cover multiple innovations and applications. ANTEC 2023 technical tracks include: Additive Manufacturing/3D printing (I and II) Additives and compatibilizers for recycling Applied rheology Automotive and sustainable transportation Bioplastics and biocomposites Composites, polymer modifiers and additives Digitalization in polymer processing Dr. Shaw's Symposium (I and II) Extrusion Foams and thermoplastic elastomers Injection molding (I and II) Medical plastics Polymer analysis Recycling Sustainable applications At the event there will also be a series of Pre-ANTEC Workshops (taking place on March 27), which will take a “deep dive” into topics of interest to ANTEC attendees, offering additional learning opportunities while at the event. Pre- ANTEC Workshops include: “Conducting a Plastic Failure Analysis,” presented by Jeffrey A. Jansen, engineering manager, The Madison Group “Materials Informatics – AI-Guided Product Development,” presented by Maryam Emami, Ph.D., CEO and founder, AI Materia “Medical Plastics and Polymers: Fundamentals and New Growth Drivers That You Need to Know,” presented by Maureen Reitman, Group vice president and principal engineer, exponent, and Len Czuba, president, Czuba Consulting “Patent Law Fundamentals for Scientists, Engineers, and Managers,” presented by Robert Migliorini, senior licensing associate, Yale University “Polymer Stabilization,” presented by Roger Avakian, owner, Avakian PolyChem Consulting, and Gary Wnek, processor and chair, Macromolecular Science and Engineering, Case Western Reserve University “Troubleshooting: Everyone’s Problem – How to Address Plastic Product Issues From the Perspective of the Product Owner,” presented by David Anzini, technical manager – R&D, Celgard LLC, and Lynzie Nebel, upstream quote engineer, Cytiva “Troubleshooting Single-Screw Extruders,” presented by Mark Spalding, R&D Fellow, Dow Inc. There will also be multiple opportunities to spend time with colleagues at SPE-hosted meetings, receptions, networking luncheons and SPE Chapter networking events. For more information about ANTEC 2023, please visit

第二届中国基因与细胞治疗青藜风云论坛（CGCT 2022）将于8月19-20日在苏州举办，本次会议将持续聚焦中国细胞基因免疫治疗学术前沿进展，涵盖更多新兴药物领域，深度挖掘和分享最新的研究成果。CGCT2022增设临床话题，邀请临床相关同仁分享临床试验成果，探讨最新的临床情况。也应行业同仁们的呼声，邀请知名资本加盟，让资本与技术强强联合，助力早期Biotech公司快速发展！Avirmax联合创始人陈海峰、原美国FDA药品评审专家郭鹏飞、博腾生物 Co-CEO Dr. Sander van Deventer、新芽基因CEO何春艳、神曦复生 （NeuExcell中国）CEO盛健、博腾生物CSO孔令洁确认加盟青藜风云论坛——基因专场。CGCT联合创始人Avirmax  Topic： AAV Production Technologies: The Latest Developments and Remaining Challenges   个人简介： 陈海峰，博士，Avirmax 联合创始人兼首席技术官/首席运营官。1982年于中山大学获得生物学学士学位，1985年于四川大学获得生物学硕士学位。1989年赴德国攻读博士研究生，1992年在德国萨尔大学获得博士学位，同年在堪萨斯州的堪萨斯大学医学中心工作并获得了美国制药公司Marion-Merrell-Dowd的博士后奖学金。博士后毕业后曾就职于 Cell Genesys、Genovo、 Avigen、 AskBio等多家基因治疗公司。2006 年，陈博士共同创立 Virovek并担任首席执行官至2019年。期间他发明了利用杆状病毒感染 Sf9细胞的“BAC-to-AAV”系统，用于大规模高效生产 AAV。2019年，陈博士共同创立了 Avirmax.，并担任首席技术官/首席运营官。陈博士曾任职于美国基因与细胞治疗学会(ASGCT)病毒基因转移载体委员会和 《分子治疗-方法与临床发展》编委。  基因论坛    CGCTNo.2  郭鹏飞药品审评专家原美国FDA  Topic： 基因治疗美国监管概述及申报策略（暂定）  个人简介： 郭鹏飞博士毕业于美国德克萨斯大学奥斯汀分校，专注于分子生物学和微生物学方面的研究。郭鹏飞博士曾任职美国FDA，先后在组织微生物实验室、细胞生物学实验室从事研究工作，并担任产品质量（CMC）审核专家。郭鹏飞博士在微生物学、细胞生物学、基因组测序和分析等多个领域具有超过20年的研发、申报注册审核经验，在美国国家科学院院刊、生物化学杂志等期刊发表多篇具有国际影响力的研究成果。  基因论坛      CGCTNo.3  Dr. Sander van DeventerCO-CEO博腾生物  Topic： AAV gene therapy: Manufacturing requirements from preclinical to commercial stages（暂定）  个人简介： 阿姆斯特丹大学医学博士，风险投资公司Forbion Capital的合伙人，原UniQure 的联合创始人和首席科学官，莱顿大学的转化胃肠病学教授。Sander 是一位卓越的科学家，发表了400多篇科学论文，组织过多次大型的国际学术会议，指导了40多名博士研究生。1998年，他与人合作创立了阿姆斯特丹分子治疗中心(AMT，即UniQure的前身)，开发基于AAV的基因治疗产品。Sander曾成功创建多个生物制药公司，在开发世界第一个靶向人TNF人鼠嵌合单克隆抗体药物（Remicade)和推动第一个基因治疗药物（Glybera)获得上市许可发挥了关键的作用，现任博腾生物CO-CEO。  基因论坛     CGCTNo.4 何春艳CEO新芽基因  Topic： 单碱基编辑治疗杜氏肌营养不良症  个人简介：  上海交通大学免疫学博士学位、曼彻斯特商学院的MBA学位、上海生物制品研究所病原生物学硕士学位，华中科技大学生物工程学学士学位。何博士在制药行业拥有十年的质量控制和研发经验。她负责了上海生物制品研究所无血清Vero细胞流感疫苗的研制开发，并在病毒产品研发方面积累了丰富的经验。何博士在商务发展，投资和孵化方面也有出色的表现。在过去的十年中，她曾在复星集团，天士力集团，阳光保险公司等公司的商务或投资部工作。她主导了万春药业和上海健耕医药投资、阳光保险对嘉和生物的股权退出。曾任上海健耕，康复之家，美国ORS董事。2018年何博士任职于复星集团创新中心投资董事总经理，负责复星高校成果转化基金，成功孵化星济生物(苏州）有限公司。2020年7月创立了苏州新芽基因生物技术有限公司。  基因论坛： 基因治疗遗传疾病（地贫、眼科、神经系统疾病）CGCTNo.5 盛健CEO神曦复生 （NeuExcell中国）  Topic： 理想照进现实—开创性神经再生基因疗法  个人简介：  复旦大学上海医学院药理学博士，执业医师，早期从事学习记忆，表观遗传学，神经精神药理学研究。有十余年医药行业研究和管理经验，曾在多家制药和生物技术公司如阿斯利康、诺华、赛诺菲等担任医学、研发和商业部门负责人。现任神曦复生生物医药有限公司（NeuExcell中国）首席执行官，致力于原位神经再生基因疗法的开发工作。  基因论坛： 基因治疗遗传疾病（地贫、眼科、神经系统疾病）CGCTNo.6  孔令洁CSO博腾生物  Topic： AAV载体的工艺开发  个人简介： 中国科学院遗传学研究所硕士，美国北卡罗来纳州立大学生物化学博士，杜克大学Dr. Joseph Nevins实验室的博士后；美国基因与细胞治疗学会基因编辑委员会理事，拥有16项基因治疗的相关专利。曾在美国默沙东制药公司和美国应用干细胞公司担任研发副首席科学家/副总监和副总裁等重要领导职位，有超过20年的生物制药、基因治疗和细胞治疗经验；领导了多项基因治疗和细胞治疗药物的研发，包括推进两个基因治疗和细胞治疗的项目在美国分别进入临床I期和临床II期阶段。  基因论坛： 工艺开发及前沿进展2022第二届中国基因与细胞治疗青藜风云论坛8月苏州，即将启幕青藜相聚，风云再起更多重磅大咖即将揭幕！大会框架大会嘉宾王立群  星奕昂生物 创始人&董事长陈海峰  Avirmax 联合创始人王立军  嘉因生物 CTO 王全军  国家北京新药安全性评价中心 研究员 唐晓文  苏州大学附属第一医院 血液内科主任医师 张   毅  郑州大学第一附属医院 教授 郭鹏飞  原美国FDA 药品审评专家 魏   东  博雅辑因 CEO 胡敏杰  般若生物 CEO 杨   林  博生吉 董事长Dr. Sander van Deventer   博腾生物 Co-CEO陈丽娟  毕诺济 执行副总裁兼首席运营官 刘滨磊  滨会生物 创始人汪伟明  鼐济医药 CSO 李航文  斯微生物 首席运营官兼董事长钱   浩  博腾生物 CTO 代红久  凯地生物 执行总裁CEO 何春艳  新芽基因 CEO 盛   健  苏州神曦复生（NeuExcell中国）CEO吴凤岚  华毅乐健 COO 孔令洁  博腾生物 CSO胡   放  康万达 董事长尚小云  茂行生物 CEO 王恩秀  南京卡提医学 创始人&CEO Meijia Yang,PhD Jiangsu ELT Research Institute  CSO章康健  元宋生物 CEO刘月光  纽伦捷生物 CSO矫士平  科士华 CEO 杨   远  贵州生诺 细胞药物管线研发负责人 陈   慧  博腾生物 分析检测&基因治疗工艺与生产副总经理 谢宏林  恺佧生物 应用总监 胡迪超  博腾生物 细胞治疗工艺开发部高级总监更多确认嘉宾持续公布中......大会现场点击可查看大图联系我们参会报名【扫描免费注册，限时抢占】✬ 生物技术、药企、科研院校和监管机构人员限时免费注册（不含餐饮，数量有限）✬ 本次报名为预登记报名，报名审核通过后将由会务组通知您！组委会联系方式：✬ 定制参展/商务赞助/媒体合作/参会报名请联系：Abby Jiang  18217659261（微信同号）✬ 学术演讲报名请联系：Ethan Liang   16620752035（微信同号）Candice Xin   18252585879（微信同号）【备注CGCT，加入青藜群聊】推荐阅读1.【青藜专栏】王恩秀：致力于实体瘤CAR-T，细胞激活是关键！

- 3Q21 GAAP EPS from continuing operations of $0.80; adjusted EPS of $1.15 - 3Q21 Net Sales of $4.3 billion, up 18 percent; organic sales up 16 percent versus the year-ago period on 10 percent volume improvement and 6 percent pricing gains - 3Q21 GAAP Income from continuing operations of $433 million; operating EBITDA of $1.09 billion, up 20 percent versus the year-ago period; operating EBITDA margin expansion of 50 basis points - Operating cash flow of $842 million; free cash flow of $634 million during the quarter - $657 million of capital returned to shareholders during the quarter through $500 million in share repurchases and $157 million in dividends [02-November-2021] WILMINGTON, Del., Nov. 2, 2021 /PRNewswire/ -- DuPont (NYSE: DD) today announced financial results for the third quarter 2021. "We delivered third quarter financial results ahead of expectations by maintaining a disciplined focus on operational excellence and pricing actions in the face of unprecedented global supply shortages, logistics challenges and sustained inflationary pressure," said Ed Breen, DuPont Executive Chairman and Chief Executive Officer. "We leveraged our global supply network to meet the needs of our customers as demand remained robust across the electronics, automotive, construction and water end-markets and continued to improve across industrial end-markets globally." "Today we also separately announced a definitive agreement to acquire Rogers Corporation(1), an advanced materials provider with superior technology innovation, applications engineering expertise, and leading end-market positions. In addition, we announced we are exploring options to divest a substantial portion of the Mobility & Materials segment(2)," Breen continued. "With these announcements, and building on our recent acquisition of Laird Performance Materials, we are significantly advancing our position as a premier multi-industrial company focused in the secular growth areas of electronics, water, protection, industrial technologies and next generation automotive. We are strengthening these pillars to further expand our capabilities to deliver differentiated, value-added technologies. These steps are expected to create tremendous opportunities for employees and unlock significant value for shareholders." Third Quarter 2021 Results Net sales totaled $4.3 billion, up 18 percent versus the year-ago period and up 16 percent on an organic(3) basis including high-single to low-double digit volume growth across each of the three reporting segments. Double-digit organic growth across Asia Pacific, Europe and North America reflects robust global customer demand in key end-markets. The organic sales growth during the quarter includes 6 percent pricing gains which primarily reflects actions taken to offset higher raw material costs. GAAP EPS from continuing operations totaled $0.80 on GAAP income from continuing operations of $433 million, versus GAAP EPS from continuing operations of $0.11 on GAAP income from continuing operations of $86 million in the year-ago period. The improvement was driven mainly by a lower share count, higher segment earnings and lower net charges associated with significant items(3). Operating EBITDA(3) was $1.09 billion, up 20 percent versus operating EBITDA(3) in the prior year. The improvement was driven by the ongoing recovery in key end-markets impacted by the COVID-19 pandemic in the year-ago period, most notably automotive, continued strength in electronics markets and the impact of the July 1, 2021 Laird Performance Materials acquisition. Operating EBITDA improvement drove 50 basis points of operating EBITDA margin expansion. Adjusted EPS(3) was $1.15, up 89% versus adjusted EPS(3) in the year-ago period primarily due to a lower share count and higher segment results. Operating cash flow in the quarter of $842 million and capital expenditures of $208 million resulted in adjusted free cash flow conversion(3) of 112 percent. Third Quarter 2021 Segment Highlights Electronics & Industrial Electronics & Industrial reported net sales of $1.5 billion, up 21 percent from the year-ago period. Volume gains delivered 9 percent organic sales growth. The July 1, 2021 acquisition of Laird Performance Materials increased net sales by 11 percent. Currency was a 1 percent tailwind. Volume growth was led by double-digit gains in Industrial Solutions with strength in consumer electronics, healthcare and industrial markets. Continued strength in Semiconductor Technologies also resulted in double-digit volume growth with demand driven by the on-going transition to more advanced technologies and growth in high performance computing and 5G communications. Within Interconnect Solutions, organic sales were down mid-single digits due to the anticipated shift in demand related to premium next-generation smartphones to the first half of the year, along with softness in automotive end-markets due to supply chain constraints. For the nine months ended September 30, 2021, organic sales for Interconnect Solutions were up high-single digits compared to the same period of the prior year. Operating EBITDA for the segment was $475 million, an increase of 13 percent from operating EBITDA of $421 million in the year-ago period. Volume gains and earnings associated with Laird Performance Materials more than offset a headwind associated with a technology sale in the prior year. Water & Protection Water & Protection reported net sales of $1.4 billion, up 12 percent from the year-ago period. Organic sales were up 11 percent on a 9 percent increase in volume and a 2 percent increase in price. Currency was a 1 percent tailwind. Sales gains versus the year-ago period were led by Safety Solutions as continued recovery in industrial end-markets resulted in significant volume improvement for aramid fibers, coupled with pricing gains. Within Shelter Solutions, high-single digit organic growth reflects continued recovery in commercial construction led by demand for solid surfaces, as well as pricing gains. Demand in North American residential construction and retail channels for do-it-yourself applications remains strong. Broad-based demand for Water Solutions technologies also remained strong, however, logistics challenges continued to impact our ability to meet demand which resulted in organic growth in the low-single digits versus the year-ago period. Operating EBITDA for the segment totaled $353 million, an increase of 12 percent compared to operating EBITDA of $314 million in the year-ago period. Volume growth and the absence of charges incurred in the prior year associated with temporarily idled facilities more than offset higher raw materials and logistics costs. Mobility & Materials Mobility & Materials reported net sales of $1.3 billion, up 30 percent from the year-ago period. Organic sales were up 28 percent on a 16 percent increase in price and a 12 percent increase in volume. Currency was a 2 percent tailwind. Sales gains were broad-based across the segment reflecting significant organic growth within each of Engineering Polymers, Performance Resins and Advanced Solutions. The local price increase of 16 percent reflects actions taken to offset raw material costs and higher metals pricing. Volume improvement reflects strong recovery from the impact of the COVID-19 pandemic including continued demand in the third quarter from automotive component manufacturers. Operating EBITDA for the segment was $280 million, an increase of 75 percent compared to operating EBITDA of $160 million in the year-ago period. The improvement was driven primarily by higher volumes, pricing gains and the absence of charges incurred in the prior year associated with temporarily idled facilities. Outlook "As our third quarter results demonstrate, the demand across our end-markets is strong and we are successfully executing against a backdrop of raw material inflation and global supply chain challenges. We moved quickly to implement strategic price increases in response to rising raw material costs and we will continue these actions in the fourth quarter to deliver neutral price/cost for the year," said Lori Koch, Chief Financial Officer of DuPont. "As we head into the fourth quarter, strong demand trends are expected to continue across almost all end-markets; however, we are seeing a deceleration in order patterns stemming from the ongoing global semiconductor chip shortage, primarily in automotive end-markets, which is consistent with the revisions to global auto build estimates which have come down 17 percent for the second half of 2021 versus estimates for the same period from just a few months ago. For full year 2021, we now estimate net sales to be between $16.34 billion and $16.40 billion, operating EBITDA between $4.14 billion and $4.17 billion and adjusted EPS in the range of $4.18 to $4.22 per share." Conference Call The Company will host a live webcast of its third quarter earnings conference call with investors to discuss its results and business outlook, along with a strategic update today at 8:00 a.m. ET and extending until approximately 9:30 a.m. ET. The slide presentation that accompanies the conference call will be posted on the DuPont's Investor Relations Events and Presentations page. A replay of the webcast also will be available on the DuPont's Investor Relations Events and Presentations page following the live event. About DuPont DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, healthcare and worker safety. More information about the company, its businesses and solutions can be found at . Investors can access information included on the Investor Relations section of the website at . DuPontTM and all products, unless otherwise noted, denoted with TM, SM or ® are trademarks, service marks or registered trademarks of affiliates of DuPont de Nemours, Inc. Overview Effective August 31, 2017, E. I. du Pont de Nemours and Company ("EID") and The Dow Chemical Company ("TDCC") each merged with subsidiaries of DowDuPont Inc. (n/k/a "DuPont") and, as a result, EID and TDCC became subsidiaries of the Company (the "DWDP Merger"). On April 1, 2019, the Company completed the separation of the materials science business through the spin-off of Dow Inc., ("Dow") including Dow's subsidiary The Dow Chemical Company (the "Dow Distribution"). On June 1, 2019, the Company completed the separation of the agriculture business through the spin-off of Corteva, Inc. ("Corteva") including Corteva's subsidiary E. I. du Pont de Nemours and Company ("EID"), (the "Corteva Distribution" and together with the Dow Distribution, the "DWDP Distributions"). On February 1, 2021, the Company completed the divestiture of the Nutrition & Biosciences ("N&B") business to International Flavors & Fragrance Inc. ("IFF") in a Reverse Morris Trust transaction (the "N&B Transaction") that resulted in IFF issuing shares to DuPont stockholders. The results of operations of DuPont for all periods presented reflect the historical financial results of N&B as discontinued operations, as applicable. The cash flows related to N&B have not been segregated and are included in the Consolidated Statements of Cash Flows for the applicable periods. In addition, the Company includes in discontinued operations activity related to the indemnification obligations pertaining to EID legacy liabilities including eligible PFAS costs under the cost sharing arrangement (the "MOU") by and between DuPont, Corteva and The Chemours Company. On July 1, 2021, DuPont completed the previously announced acquisition (the "Laird PM Acquisition") of the Laird Performance Materials business, ("Laird PM"). On November 2, 2021, DuPont announced it has entered definitive agreements to acquire Rogers Corporation ("Rogers"), (the "Intended Rogers Acquisition"). The transaction is subject to approval by Rogers shareholders, regulatory approvals and customary closing conditions. On November 2, 2021, DuPont announced that it has initiated a divestiture process (the "In-Scope M&M Divestiture Process") related to a substantial portion of its Mobility & Materials segment, (the "In-Scope M&M Businesses"). The outcome of which, including the entry into definitive agreements, is subject to approval of the DuPont Board of Directors. Cautionary Statement Regarding Forward Looking Statements This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," and similar expressions and variations or negatives of these words. Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties and assumptions, many of which that are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) in connection with the Intended Rogers Acquisition, the failure to (x) obtain the necessary approval from Rogers' shareholders, regulatory approvals, or anticipated tax treatment, or (y) satisfy any of the other conditions to closing; (ii) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies could impact the value, timing or pursuit of the closing of the Intended Rogers Acquisition; (iii) the timing and outcome of the In-Scope M&M Divestiture Process and the risks, costs and ability to realize benefits from the pursuit of any disposition of the In-Scope M&M Businesses resulting therefrom; (iv) the ability to achieve expected benefits, synergies and operating efficiencies in connection with the Laird PM Acquisition within the expected time frames or at all or to successfully integrate Laird PM; (v) ability to achieve anticipated tax treatments in connection with the N&B Transaction, Laird PM Acquisition or the DWDP Distributions; (vi) changes in relevant tax and other laws; (vii) indemnification of certain legacy liabilities of EID in connection with the Corteva Distribution; (viii) risks and costs related to the performance under and impact of the cost sharing arrangement by and between DuPont, Corteva and The Chemours Company related to future eligible PFAS costs; (ix) failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes, including meeting conditions under the Letter Agreement entered in connection with the Corteva Distribution, related to the transfer of certain levels of assets and businesses; (x) uncertainty as to the long-term value of DuPont common stock; (xi) risks and uncertainties related to the novel coronavirus (COVID-19) and the responses thereto (such as voluntary and in some cases, mandatory quarantines as well as shut downs and other restrictions on travel and commercial, social and other activities) on DuPont's business, results of operations, access to sources of liquidity and financial condition which depend on highly uncertain and unpredictable future developments, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume; and (xii) other risks to DuPont's business, operations; each as further discussed in detail in and results of operations as discussed in DuPont's annual report on Form 10-K for the year ended December 31, 2020 and its subsequent reports on Form 10-Q and Form 8-K. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont's consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Non-GAAP Financial Measures This earnings release includes information that does not conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") and are considered non-GAAP measures. Management uses these measures internally for planning, forecasting and evaluating the performance of the Company, including allocating resources. DuPont's management believes these non-GAAP financial measures are useful to investors because they provide additional information related to the ongoing performance of DuPont to offer a more meaningful comparison related to future results of operations. These non-GAAP financial measures supplement disclosures prepared in accordance with U.S. GAAP, and should not be viewed as an alternative to U.S. GAAP. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided in the Selected Financial Information and Non-GAAP Measures starting on page 11 and in the Reconciliation to Non-GAAP Measures on the Investors section of the Company's website. Non-GAAP measures included in this release are defined below. The Company has not provided forward-looking U.S. GAAP financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most comparable U.S. GAAP financial measures on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of certain future events. These events include, among others, the impact of portfolio changes, including asset sales, mergers, acquisitions, and divestitures; contingent liabilities related to litigation, environmental and indemnifications matters; impairments and discrete tax items. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP results for the guidance period. Adjusted earnings per common share from continuing operations - diluted ("Adjusted EPS"), is defined as earnings per common share from continuing operations - diluted, excluding the after-tax impact of significant items, after-tax impact of amortization expense of intangibles and the after-tax impact of non-operating pension / other post employment benefits ("OPEB") benefits / charges. Management estimates amortization expense in 2021 associated with intangibles to be approximately $720 million on a pre-tax basis, or approximately $1.03 per share. Operating EBITDA, is defined as earnings (i.e. income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, adjusted to exclude significant items. Operating EBITDA margin is calculated as operating EBITDA divided by net sales. Operating EBITDA leverage is calculated as the year-over-year percentage change in operating EBITDA divided by the year-over-year percentage change in net sales. Significant items are items that arise outside the ordinary course of the Company's business that management believes may cause misinterpretation of underlying business performance, both historical and future, based on a combination of some or all of the item's size, unusual nature and infrequent occurrence. Management classifies as significant items certain costs and expenses associated with integration and separation activities related to transformational acquisitions and divestitures as they are considered unrelated to ongoing business performance. Organic Sales is defined as net sales excluding the impacts of currency and portfolio. Free cash flow is defined as cash provided by/used for operating activities less capital expenditures. As a result, free cash flow represents cash that is available to the Company, after investing in its asset base, to fund obligations using the Company's primary source of liquidity, cash provided by operating activities. Management believes free cash flow, even though it may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company's cash flow and financial performance, and it is an integral measure used in the Company's financial planning process. Free cash flow conversion is defined as free cash flow divided by net income adjusted to exclude the after-tax impact of non-cash impairment charges, gains or losses on divestitures, and amortization expense of intangibles. Company Codes: NYSE:DD, NYSE:ROG